Ancillary Material Considerations for a Seamless Transition into GMP Manufacturing
16 May 2023
This Briefing from Advanced Therapies Week 2023 focusses on ancillary material considerations to facilitate a seamless transition into GMP manufacturing.
During this session, Bernd Leistler, Vice President of Production at Sartorius CellGenix is joined by Tess Kitchener, Vice President, BaseCamp Business Development at Elevatebio, Isaac Zentner, Associate Director of Process Development at Carisma Therapeutics, Stefano Baila, Managing Director at Eurofins and Lili Belcastro, Senior Principal Scientist, Cell and Gene Therapy Raw Materials at Bristol Myers Squibb.
This Briefing was presented at Advanced Therapies Week 2023, in partnership with Sartorius CellGenix.
More like this
Eureka Therapeutics Awarded $10.6M CIRM Grant for T-Cell Therapy in Pediatric Liver Cancer
Eureka Therapeutics has received a $10.6 million grant from the California Institute for Regenerative Medicine (CIRM) to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of refractory/relapsed liver cancer for pediatric patients.
8 June 2023
Cell and Gene Therapy Catapult Open New Edinburgh, UK, Facilities
UK-based independent innovation and technology organization Cell and Gene Therapy Catapult (CGT Catapult), has officially opened new laboratories and offices in Edinburgh, Scotland, UK, BioQuarter – enhancing Edinburgh’s role as a hub for cell therapies.
7 June 2023
BioCentriq® Unveils LEAP™ Advanced Therapy Platform, Enabling Rapid Patient Access for Early-Stage Biotech Companies
BioCentriq launched their new LEAP™ Advanced Therapy Platform at the 29th International Society for Cell & Gene Therapy (ISCT) annual event with proven assets and expertise to help early-stage biotech companies effectively deliver to patients without compromising quality.
5 June 2023